Figure 8.

Cardiac levels of Bcl-2, a marker of anti-apoptosis, and Bax and Cyto-C, two markers of apoptosis, in mice under sham, B307, DOX, and B307+DOX treatments.

Notes: (A) IHC staining illustrates that cardiac expression levels of Bcl-2 in the mice were visibly enhanced under oral B307 treatment but were visibly reduced under DOX treatment. As to the DOX-treated mice, cardiac expression levels of Bcl-2 were visibly enhanced under oral B307 treatment. On the other hand, cardiac expression levels of Bax and Cyto-C in the mice were visibly reduced under oral B307 treatment but were visibly enhanced under DOX treatment. As to the DOX-treated mice, cardiac expression levels of Bax and Cyto-C were visibly reduced under oral B307 treatment. (B) Western blotting analysis shows the following: (a) expression levels of cardiac Bcl-2, Bax, and Cyto-C under sham, B307, DOX, and B307+DOX treatments and (b) the quantified ratio of Bcl-2/Bax in the heart tissue of the mice was significantly increased under oral B307 treatment but were significantly reduced under DOX treatment. As to the DOX-treated mice, the quantified ratio of Bcl-2/Bax in the heart tissue was significantly increased under oral B307 treatment. On the other hand, quantified Cyto-C levels in the heart tissue of the mice were significantly decreased under oral B307 treatment but were significantly enhanced under DOX treatment. As to the DOX-treated mice, quantified Cyto-C levels in the heart tissue were significantly reduced under oral B307 treatment. The number of mice under sham, B307, DOX, and B307+DOX treatments was six for each group. Values are mean ± SEM (*P<0.05, **P<0.01, two-way ANOVA followed by a Student–Newman–Keuls multiple comparisons posttest).

Abbreviations: Bcl-2, B-cell lymphoma 2; Bax, BCL2-associated X protein; Cyto-C, cytochrome C; DOX, doxorubicin; kDa, kilodalton; IHC, immunohistochemical; SEM, standard error of the mean; ANOVA, analysis of variance.